
==== Front
Cancer Diagn Progn
Cancer Diagn Progn
Cancer Diagnosis & Prognosis
2732-7787
International Institute of Anticancer Research

10.21873/cdp.10381
Research Article
Successful Use of Cemiplimab in a Very Elderly Patient With Cutaneous Squamous Cell Carcinoma
GAMBALE ELISABETTA 12
VENTURI GIULIA 12
GUARINO ADRIANA 12
VASCOTTO ISMAELA ANNA 12
PILLOZZI SERENA 2
DESIDERI ISACCO 3
DONI LAURA 2
ANTONUZZO LORENZO 12
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
2 Clinical Oncology, Careggi University Hospital, Florence, Italy
3 M. Serio Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy
Elisabetta Gambale, Clinical Oncology, Careggi University Hospital, L.go Brambilla 3, 50134, Florence, Italy. Tel: +39 0557948406 gambaleelisabetta@gmail.com
1 9 2024
Sep-Oct 2024
4 5 680683
26 5 2024
21 6 2024
26 7 2024
©2024 The Author(s). Published by the International Institute of Anticancer Research.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license
Background/Aim

Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with significant morbidity and mortality, particularly in advanced stages. Treatment options for metastatic cutaneous SCC in very elderly patients are limited due to concerns about treatment tolerability and potential adverse effects.

Case Report

We report the case of a 90-year-old female patient with metastatic cutaneous SCC who was treated with cemiplimab, a monoclonal antibody (m-Ab) against programmed cell death protein 1 (PD-1), in combination with radiotherapy. The patient received cemiplimab for a limited period, during which time she demonstrated significant clinical improvement without severe adverse events. Radiotherapy was performed as a locoregional treatment with the aim to enhance immunotherapy efficacy.

Discussion

This case highlights the feasibility and effectiveness of cemiplimab in very elderly patients with metastatic cutaneous SCC. Despite the common apprehensions regarding the use of immunotherapy in this age group, our patient tolerated cemiplimab well, and the combination with radiotherapy proved beneficial. This suggests that even in very elderly patients, short-term use of cemiplimab, in conjunction with locoregional treatments such as radiotherapy, can be a viable and successful therapeutic approach.

Conclusion

Cemiplimab, even in combination with radiotherapy, can be effectively and safely administered to very elderly patients with metastatic cutaneous SCC. This case supports the consideration of immunotherapy, even for a limited duration, as a practical option in the management of advanced cutaneous SCC in elderly patients, expanding the potential treatment strategies for this population.

Cutaneous squamous cell carcinoma
immune checkpoint inhibitor
radiotherapy
elderly
==== Body
pmcCutaneous squamous cell carcinoma (SCC) is described to represent around 20% of non-melanomatous skin cancer, with an increasing incidence, particularly in men over the age of 80 years (1). Cutaneous SCC is likely more common in older patients due to cumulative UV-radiation exposure, with rates 5-10 times higher in those aged over 75 years (2). The therapeutic management of advanced or metastatic cutaneous SCC can be challenging, especially in very elderly patients who often have multiple comorbidities and reduced functional reserve. Recently immune checkpoint inhibitors (ICI) such as cemiplimab, a monoclonal antibody (mAb) against programmed death 1 (PD-1), have become the standard of care for the management of patients with advanced cutaneous SCC who cannot be cured with surgery or radiotherapy. However, data on the use of immunotherapy in very elderly patients are limited and sometimes conflicting. The elderly population is often underrepresented in clinical trials, making it difficult to draw definitive conclusions about the efficacy and safety of these therapies in this age group. Additionally, there is widespread concern about the potential deterioration in the overall health status and increased risk of adverse events following immunotherapeutic treatments in very elderly patients (3,4). This is particularly relevant for advanced cutaneous SCC, with the cemiplimab pivotal study having a median cohort age of 71 years and median ages of 77 and 79 years reported in real-world population studies from France (5) and Italy (6), respectively.

However, there is growing literature showing that ICI can be effectively and safely administered to older patients (7). In this case report, we present the case of a very elderly patient with cutaneous SCC successfully treated with cemiplimab. Notably, we also integrated the treatment with locoregional radiotherapy, achieving a synergistic and excellent outcome. This case emphasizes the role of radiotherapy in conjunction with immunotherapy in locally advanced cutaneous SCC, including scenarios of oligoprogression during immunotherapy. Our objective is to highlight the fact that immunotherapy can not only be effective but also safe in this population, without compromising overall health status and without a significant increase in adverse events. This case report aims to help bridge the existing data gap, supporting the use of immunotherapy even in very elderly patients.

Case Report

A 90-year-old female was diagnosed in April 2019 with a cutaneous SCC of the right thigh. She presented an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 2, with Geriatric 8 (G8) score (8) of 15, Lee’s prognostic index of 13 and Charlson comorbidity index of 6. In subsequent years the patient underwent regular dermatological follow-up. In May 2022, due to biopsy findings of right inguinal lymphadenopathy, the patient underwent instrumental investigations. A whole-body computed tomography (CT) scan showed multiple inguinal and iliac lymphadenopaties, indicating the patient was not suitable for curative locoregional treatment. A confirmatory excisional biopsy of right inguinal adenopathy was performed, reporting metastasis of SCC. Thus, in August 2022, first-line therapy with cemiplimab at 350 mg intravenously every 3 weeks was started. After an initial partial response at the CT scan performed in December 2022, she experienced objective and radiological progressive disease at the radiological tumor assessment performed in March 2023, with enlargement and ulceration of right inguinal adenopathy (Figure 1). After multidisciplinary discussion, continuation of cemiplimab and radiotherapy to the site of right inguinal lymph node progression were prescribed. In April 2023, the patient received external beam radiotherapy (five radiotherapy sessions for a total of 25 Gy) to the right inguinal lymph node and continued cemiplimab, achieving rapid objective improvement (Figure 1). This was confirmed at whole-body CT scan performed in July 2023, not only of the irradiated right inguinal site, but also of the iliac lymphadenopathy. Unfortunately, the patient’s ECOG PS score declined during cemiplimab and radiotherapy administration with a final ECOG PS of 3. Furthermore, the nutritional state worsened, and the patient lost weight. Thus, in August 2023, after 1 year of treatment and due to the objective complete response, cemiplimab was permanently discontinued, with rapid clinical improvement of the patient. The latest whole-body CT scan and clinical evaluation performed in April 2024 confirmed complete response, with ECOG PS of 1.

Figure 1 Results of cemiplimab associated with concurrent radiotherapy in a 90-year-old woman with right inguinal lymph node metastasis from cutaneous squamous cell carcinoma of the right thigh. Images taken after five radiotherapy sessions for a total of 25 Gy (A) and after 1 (B) and 3 (C) months of concurrent cemiplimab.

Ethical considerations. Written informed consent for publication of clinical details and clinical images was obtained from the patient.

Discussion

Updated 2023 European guidelines now recommend the use of anti-PD1 agents as a first-line treatment in patients with advanced cutaneous SCC who are not candidates for curative surgery or radiation (9) based on several pivotal clinical trials that have paved a busy road leading to improved clinical management of patients with SCC (9,10). However, although elderly and frail patients with ECOG PS ≥2 are particularly affected by advanced cutaneous SCC, the proportion of this specific population enrolled in clinical studies is limited, likely due to investigators’ worries about the drug safety profile in this frail population, but also in light of the widespread concept that immunotherapy is less effective due to the senescence of the immune system with ageing (11).

Nevertheless, multicenter retrospective studies, aiming to assess the risk/benefit ratio of immunotherapy for advanced cutaneous SCC in elderly patients, confirmed the efficacy of anti-PD1 agents in treating these populations in a real-life setting with no significant loss of efficiency compared to younger patients (4-6,12,13). Intriguingly, one retrospective report even had the unexpected finding that elderly patients with metastatic melanoma actually fared better on immune checkpoint inhibitors, with a reported progression-free survival (PFS) on treatment with PD-1 inhibitors greater than expected (13).

In light of this evidence, age should no longer be a limiting factor when prescribing immunotherapy. However, adverse events, including weight loss, may have major consequences in these frail patients and must be closely monitored, particularly using specific geriatric evaluation tools at baseline and regularly throughout the course of treatment to ensure that it remains beneficial (14-16). Interestingly, our patient experienced an objective response not only of the irradiated right inguinal lymph node, but also of the iliac adenopathy, suggesting a potential abscopal effect of radiotherapy when combined with immunotherapy (17-22). The use of concurrent radiotherapy will hopefully undergo closer evaluation in larger studies.

Intriguingly, our patient received cemiplimab therapy for only 1 year, achieving a significant objective response. This suggests that a shorter duration of treatment may be sufficient to reach the necessary efficacy in this category of patients. Recent studies have reported the administration of cemiplimab for a limited period, supporting this observation (23). However, the shortened duration of cemiplimab treatment requires further prospective studies to validate these findings.

Our case report, confirming immunotherapy as an effective strategy to fight cancer, reflects the trend that more and more patients with cutaneous cancer, even if elderly, can successfully receive this type of treatment. Thus, the inclusion of elderly patients in clinical trials seems to be imperative and systematic reporting of subgroup analyses by age may shed light on their optimal management.

Conflicts of Interest

The Authors declare that the research was conducted in the absence of commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

All the Authors contributed to the preparation of this work and read and approved the final article. EG, GV, AG, IAV and LD were responsible for collecting the data and drafting the first copy. EG, ID, and LD were responsible for editing the article. LA, EG, and SP were responsible for the final editing and preparation of the article for submission.
==== Refs
1 Keim U Katalinic A Holleczek B Wakkee M Garbe C Leiter U Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland Eur J Cancer 2023 183 60 68 10.1016/j.ejca.2023.01.017 36801607
2 Thai AA Lim AM Solomon BJ Rischin D Biology and treatment advances in cutaneous squamous cell carcinoma Cancers (Basel) 2021 13(22) 5645 10.3390/cancers13225645 34830796
3 Sedrak MS Mohile SG Sun V Sun CL Chen BT Li D Wong AR George K Padam S Liu J Katheria V Dale W Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists J Geriatr Oncol 2020 11(2) 327 334 10.1016/j.jgo.2019.07.017 31375399
4 Nebhan CA Cortellini A Ma W Ganta T Song H Ye F Irlmeier R Debnath N Saeed A Radford M Alahmadi A Diamond A Hoimes C Ramaiya N Presley CJ Owen DH Abou Alaiwi S Nassar A Ricciuti B Lamberti G Bersanelli M Casartelli C Buti S Marchetti P Giusti R Filetti M Vanella V Mallardo D Macherla S Sussman TA Botticelli A Galetta D Catino A Pizzutilo P Genova C Dal Bello MG Kalofonou F Daniels E Ascierto PA Pinato DJ Choueiri TK Johnson DB Marron TU Wang Y Naqash AR Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study JAMA Oncol 2021 7(12) 1856 1861 10.1001/jamaoncol.2021.4960 34734989
5 Hober C Fredeau L Pham-Ledard A Boubaya M Herms F Celerier P Aubin F Beneton N Dinulescu M Jannic A Meyer N Duval-Modeste AB Cesaire L Neidhardt ÈM Archier É Dréno B Lesage C Berthin C Kramkimel N Grange F de Quatrebarbes J Stoebner PE Poulalhon N Arnault JP Abed S Bonniaud B Darras S Heidelberger V Devaux S Moncourier M Misery L Mansard S Etienne M Brunet-Possenti F Jacobzone C Lesbazeilles R Skowron F Sanchez J Catala S Samimi M Tazi Y Spaeth D Gaudy-Marqueste C Collard O Triller R Pracht M Dumas M Peuvrel L Combe P Lauche O Guillet P Reguerre Y Kupfer-Bessaguet I Solub D Schoeffler A Bedane C Quéreux G Dalac S Mortier L Maubec È Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI study group Cancers (Basel) 2021 13(14) 3547 10.3390/cancers13143547 34298764
6 Baggi A Quaglino P Rubatto M Depenni R Guida M Ascierto PA Trojaniello C Queirolo P Saponara M Peris K Spagnolo F Bianchi L De Galitiis F Potenza MC Proietti I Marconcini R Botticelli A Barbieri V Licitra L Alfieri S Ficorella C Cortellini A Fargnoli MC Troiani T Tondulli L Bossi P Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma Eur J Cancer 2021 157 250 258 10.1016/j.ejca.2021.08.018 34536948
7 Johns AC Wei L Grogan M Hoyd R Bridges JFP Patel SH Li M Husain M Kendra KL Otterson GA Burkart JT Rosko AE Andersen BL Carbone DP Owen DH Spakowicz DJ Presley CJ Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer J Geriatr Oncol 2021 12(5) 813 819 10.1016/j.jgo.2021.02.002 33627226
8 van Walree IC Scheepers E van Huis-Tanja L Emmelot-Vonk MH Bellera C Soubeyran P Hamaker ME A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer J Geriatr Oncol 2019 10(6) 847 858 10.1016/j.jgo.2019.04.016 31078444
9 Stratigos AJ Garbe C Dessinioti C Lebbe C van Akkooi A Bataille V Bastholt L Dreno B Dummer R Fargnoli MC Forsea AM Harwood CA Hauschild A Hoeller C Kandolf-Sekulovic L Kaufmann R Kelleners-Smeets NW Lallas A Leiter U Malvehy J Del Marmol V Moreno-Ramirez D Pellacani G Peris K Saiag P Tagliaferri L Trakatelli M Ioannides D Vieira R Zalaudek I Arenberger P Eggermont AMM Röcken M Grob JJ Lorigan P EADO EDF ESTRO UEMS EADV EORTC European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023 Eur J Cancer 2023 193 113252 10.1016/j.ejca.2023.113252 37708630
10 Migden MR Khushalani NI Chang ALS Lewis KD Schmults CD Hernandez-Aya L Meier F Schadendorf D Guminski A Hauschild A Wong DJ Daniels GA Berking C Jankovic V Stankevich E Booth J Li S Weinreich DM Yancopoulos GD Lowy I Fury MG Rischin D Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial Lancet Oncol 2020 21(2) 294 305 10.1016/S1470-2045(19)30728-4 31952975
11 Bastiaannet E Battisti N Loh KP de Glas N Soto-Perez-de-Celis E Baldini C Kapiteijn E Lichtman S Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper J Geriatr Oncol 2019 10(3) 389 397 10.1016/j.jgo.2018.06.009 30025821
12 McLean LS Lim AM Bressel M Thai AA Rischin D Real-world experience of immune-checkpoint inhibitors in older patients with advanced cutaneous squamous cell carcinoma Drugs Aging 2024 41(3) 271 281 10.1007/s40266-024-01095-z 38446342
13 Ibrahim T Mateus C Baz M Robert C Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study Cancer Immunol Immunother 2018 67(10) 1571 1578 10.1007/s00262-018-2219-8 30056599
14 Strippoli S Fanizzi A Quaresmini D Nardone A Armenio A Figliuolo F Filotico R Fucci L Mele F Traversa M De Luca F Montagna ES Ruggieri E Ferraiuolo S Macina F Tommasi S Sciacovelli AM De Risi I Albano A Massafra R Guida M Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy Front Oncol 2021 11 686308 10.3389/fonc.2021.686308 34820323
15 Koch Hein EC Vilbert M Hirsch I Fernando Ribeiro M Muniz TP Fournier C Abdulalem K Saldanha EF Martinez E Spreafico A Hogg DH Butler MO Saibil SD Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world experience from a canadian comprehensive cancer centre Cancers (Basel) 2023 15(17) 4312 10.3390/cancers15174312 37686588
16 Jang RW Caraiscos VB Swami N Banerjee S Mak E Kaya E Rodin G Bryson J Ridley JZ Le LW Zimmermann C Simple prognostic model for patients with advanced cancer based on performance status J Oncol Pract 2014 10(5) e335 e341 10.1200/JOP.2014.001457 25118208
17 Demaria S Golden EB Formenti SC Role of local radiation therapy in cancer immunotherapy JAMA Oncol 2015 1(9) 1325 10.1001/jamaoncol.2015.2756 26270858
18 Asna N Livoff A Batash R Debbi R Schaffer P Rivkind T Schaffer M Radiation therapy and immunotherapy-a potential combination in cancer treatment Curr Oncol 2018 25(5) e454 e460 10.3747/co.25.4002 30464697
19 Ngwa W Irabor OC Schoenfeld JD Hesser J Demaria S Formenti SC Using immunotherapy to boost the abscopal effect Nat Rev Cancer 2018 18(5) 313 322 10.1038/nrc.2018.6 29449659
20 Koller KM Mackley HB Liu J Wagner H Talamo G Schell TD Pameijer C Neves RI Anderson B Kokolus KM Mallon CA Drabick JJ Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone Cancer Biol Ther 2017 18(1) 36 42 10.1080/15384047.2016.1264543 27905824
21 Forner D Horwich P Trites JR Hollenhorst H Bullock M Lamond NWD The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review Curr Oncol 2020 27(6) 330 335 10.3747/co.27.6687 33380865
22 Bailly-Caillé B Kottler D Morello R Lecornu M Kao W Meyer E Dompmartin A L’Orphelin JM Real-life study of the benefit of concomitant radiotherapy with cemiplimab in advanced cutaneous squamous cell carcinoma (cSCC): a retrospective cohort study Cancers (Basel) 2023 15(2) 495 10.3390/cancers15020495 36672444
23 Mallardo D Sparano F Vitale MG Trojaniello C Fordellone M Cioli E Esposito A Festino L Mallardo M Vanella V Facchini BA De Filippi R Meinardi P Ottaviano M Caracò C Simeone E Ascierto PA Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma Cancer Immunol Immunother 2024 73(8) 160 10.1007/s00262-024-03728-z 38850335
